10-Q: Actinium Pharmaceuticals Reports Q2 2024 Results, Provides Update on Iomab-B Regulatory Pathway

Actinium Pharmaceuticals reported its second quarter 2024 financial results and provided an update on the regulatory pathway for its lead drug candidate, Iomab-B, noting the FDA requires an additional clinical trial.

Summary

• Actinium Pharmaceuticals reported a net loss of $11.4 million for the three months ended June 30, 2024, a decrease from the $15.2 million loss in the same period of 2023.
• The company's research and development expenses decreased to $8.8 million for the quarter, down from $11.1 million in the prior year, primarily due to lower CMC expenses.
• General and administrative expenses also decreased to $3.6 million from $4.6 million year-over-year.
• Net loss for the six months ended June 30, 2024 was $20.0 million, compared to $26.2 million for the same period in 2023.
• The company's cash and cash equivalents increased to $86.0 million as of June 30, 2024, up from $76.7 million at the end of 2023.
• Actinium sold 2.9 million shares of common stock in the first half of 2024, generating net proceeds of $24.7 million.
• The FDA has indicated that the SIERRA trial alone is not sufficient for BLA filing for Iomab-B and requires an additional clinical trial demonstrating an overall survival benefit.
• The company intends to seek a strategic partner for Iomab-B in the U.S. after further discussions with the FDA.
• Actinium has a licensing agreement with Immedica for Iomab-B in the EUMENA region, and Immedica is preparing the MAA filing.
• The company is advancing Actimab-A in collaboration with the NCI, with preclinical data showing promise in combination with menin inhibitors.
• Iomab-ACT is being studied in clinical trials for conditioning prior to cell and gene therapies, including a trial with a commercial CAR-T therapy.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company shows progress in its pipeline and financial position, the FDA's requirement for an additional clinical trial for Iomab-B is a significant setback. The need for a strategic partner and potential capital raise also add uncertainty.

Positives

• The company's net loss decreased year-over-year for both the quarter and six-month period.
• Cash and cash equivalents increased, providing a stronger financial position.
• The company is actively advancing its pipeline with multiple clinical trials and collaborations.
• Preclinical data for Actimab-A in combination with menin inhibitors is promising.
• The company has a licensing agreement with Immedica for Iomab-B in the EUMENA region.

Negatives

• The FDA has determined that the SIERRA trial alone is not sufficient for BLA filing for Iomab-B.
• An additional clinical trial is required for Iomab-B, which will likely delay the regulatory approval process.
• The company will need to seek a strategic partner for Iomab-B in the U.S.

Risks

• The need for an additional clinical trial for Iomab-B introduces further uncertainty and potential delays.
• The company's reliance on third-party manufacturers and suppliers poses a risk to its supply chain.
• The company is subject to the risks associated with clinical trials, including potential delays, failures, and adverse events.
• The company is subject to the risks associated with regulatory approvals, including potential delays, rejections, and post-approval requirements.
• The company is subject to the risks associated with commercialization, including market acceptance, competition, and reimbursement challenges.

Future Outlook

The company expects its existing resources will be sufficient to fund planned operations for more than 12 months. Actinium intends to further discuss the specifics of the additional clinical trial for Iomab-B with the FDA and seek a strategic partner for the U.S. market. The company also plans to continue advancing its other pipeline programs, including Actimab-A and Iomab-ACT.

Management Comments

• The company is focused on developing Antibody Radiation Conjugates (ARCs) and targeted radiotherapies to improve outcomes for patients with relapsed or refractory cancer.
• The company believes its technology platform and intellectual property are industry-leading.
• The company is building an integrated, specialty radiotherapeutics company.
• The company is leveraging its experience in conducting late-stage clinical trials and coordinating the manufacturing and clinical supply chain of radiotherapeutics.
• The company is attempting to leverage the mutation-agnostic ability of Ac-225 to establish Actimab-A as a backbone therapy in AML.
• The company believes its findings show that Actimab-A has the potential to selectively deplete MDSCs in lung, colorectal and other cancers.
• The company believes an opportunity exists for Iomab-ACT to potentially generate significant revenue, if it can provide one or more clinical benefits related to lower CRS, less neurotoxicity, longer duration of response or a higher overall success rate of cellular therapy due to benefits of targeted conditioning.

Industry Context

The announcement comes amid increasing interest in targeted radiotherapies for cancer treatment. The FDA's requirement for an additional clinical trial for Iomab-B highlights the rigorous regulatory standards for new cancer therapies. The company's focus on relapsed or refractory disease aligns with the industry's need for better treatment options for these patient populations. The collaboration with the NCI and the development of Iomab-ACT for cell and gene therapies reflect the growing trend of combining different treatment modalities to improve patient outcomes.

Comparison to Industry Standards

• The FDA's decision to require an overall survival endpoint for Iomab-B is consistent with the current trend in AML drug approvals, where overall survival has become a key metric.
• The company's focus on targeted radiotherapies aligns with the broader industry trend of developing more precise and effective cancer treatments, as seen with companies like Novartis (Pluvicto, Lutathera) and Bayer (Xofigo).
• Actinium's approach of using alpha-emitting isotopes like Ac-225 is similar to other companies exploring alpha therapies, such as Fusion Pharmaceuticals and Telix Pharmaceuticals.
• The company's collaboration with the NCI is similar to other biotech companies partnering with government research institutions to accelerate drug development.
• The development of Iomab-ACT for conditioning prior to cell and gene therapies is in line with the industry's efforts to improve the safety and efficacy of these treatments, as seen with companies like Allogene and CRISPR Therapeutics.
• The company's manufacturing and supply chain expertise in radiotherapeutics is a key differentiator, as this is a complex area with specific requirements, unlike small molecule radioligands.

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to the regulatory update on Iomab-B.
• Patients with relapsed or refractory AML may experience a delay in the availability of Iomab-B.
• Employees may be affected by the company's need to manage growth and potential changes in strategy.
• Partners and collaborators may be impacted by the company's need to seek a strategic partner for Iomab-B.

Next Steps

• The company will further discuss the specifics of the additional clinical trial for Iomab-B with the FDA.
• The company will seek a strategic partner for Iomab-B in the U.S.
• The company will continue to advance its other pipeline programs, including Actimab-A and Iomab-ACT.
• Immedica will continue preparing the MAA filing for Iomab-B in the EUMENA region.

Key Dates

Keywords

Actinium Pharmaceuticals, Iomab-B, Actimab-A, Iomab-ACT, AML, radiotherapy, clinical trial, FDA, BLA, Ac-225, CAR-T, bone marrow transplant, oncology, hematology